LEP and myeloproliferative disorder: We tested this hypothesis by treating otherwise healthy mice with the selective Jak2 inhibitor NVP-BSK805, which was proven useful against myeloproliferative neoplasms using rodent models (Baffert et al., 2010), and evaluated changes in FI, BW and body composition and interference with the action of leptin on feeding behavior and on specific molecular markers.